Medartis lifts 2025 sales outlook after 15.3% H1 growth, posts small loss

Medartis Holding AG reported a robust 15.3% increase in first-half organic sales, reaching CHF 123 million, and subsequently raised its full-year 2025 organic core sales growth outlook to 14-16% from 13-15%. Despite this strong operational momentum and an unchanged high-teens core EBITDA margin, the orthopedic company posted a core net loss of CHF 0.4 million for the period, primarily due to CHF 5 million in foreign exchange losses and CHF 3.2 million in financing costs from 2024 convertible bonds. This update highlights solid top-line performance and an improved growth forecast, tempered by specific financial headwinds impacting net profitability.

Analysis

Medartis Holding AG demonstrated strong operational performance in the first half, headlined by a 15.3% increase in organic sales and an upward revision of its full-year 2025 sales growth forecast to a 14-16% range. This top-line momentum was broad-based, with constant-currency sales growth of 16% in EMEA and 16.2% in the U.S., the latter benefiting from a successful distributor network restructuring. Despite this robust growth, profitability at the net level was eroded, swinging from a CHF 7.3 million profit to a CHF 0.4 million core net loss. This was explicitly attributed to CHF 5 million in foreign exchange losses and CHF 3.2 million in financing costs from new convertible bonds, rather than operational weakness. Gross margin contracted to 80.7% from 83.4%, pressured by Swiss Franc appreciation, U.S. tariffs, and dilution from recent acquisitions and distribution deals. However, the company maintained a stable core EBITDA margin of 17.8%, indicating that underlying operational profitability remains intact despite these external and strategic pressures.

Key Decisions for Investors

• Investors should focus on the strong operational metrics, such as the 15.3% organic sales growth and raised 2025 guidance, as primary indicators of the company's health, while treating the net loss as largely driven by non-operational factors like FX and financing costs.
• The contraction in gross margin to 80.7% warrants close monitoring, as continued pressure from Swiss Franc strength, U.S. tariffs, or acquisition integration could eventually challenge the stable core EBITDA margin outlook.
• Consider the positive impact of the U.S. distributor restructuring, which fueled 16.2% regional growth, as evidence of effective strategic execution that could unlock further value as the company moves past current macroeconomic headwinds.